Afamitresgene Autoleucel
Afamitresgene autoleucel uses a patient's T cells (a type of immune system cell). In the lab, a special receptor is added to the T cells, allowing them to recognize an antigen (protein) called MAGE-A4, found on some cancer cells. These modified T cells are then grown in large numbers in the lab and infused back into the patient. Once inside the body, afamitresgene autoleucel binds to the MAGE-A4 antigen on cancer cells, helping the immune system to attack and kill the cancer cells. This treatment is a type of cellular immunotherapy called T-cell receptor therapy.
FDA label information for this drug is available at DailyMed.
Use in Cancer
Afamitresgene autoleucel is approved to treat adults with:
- synovial sarcoma that has spread to other parts of the body or cannot be removed by surgery. It is used in patients who have received chemotherapy, who have the blood antigens HLA-A*02:01P, HLA-A*02:02P, HLA-A*02:03P, or HLA-A*02:06P, and whose cancer has the MAGE-A4 antigen.
Afamitresgene autoleucel is approved under FDA’s Accelerated Approval Program. As a condition of approval, confirmatory trial(s) must show that it provides a clinical benefit in these patients.
Afamitresgene autoleucel is also being studied in the treatment of other types of cancer.
More About Afamitresgene Autoleucel
Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
Research Results and Related Resources
FDA Approves Engineered Cell Therapy for Advanced Synovial Sarcoma
Targeted Therapy to Treat Cancer
Clinical Trials Accepting Patients
Find Clinical Trials for Afamitresgene Autoleucel - Check for trials from NCI's list of cancer clinical trials now accepting patients.